Proven Med Tech Leader with an Established Track Record of Commercial Success and Optimizing Shareholder Value Leading to over $3.4 Billion in Successful ExitsWhite Bear Lake, Minnesota--(Newsfile Corp. - April 16, 2026)

<p>Proven Med Tech Leader with an Established Track Record of Commercial Success and Optimizing Shareholder Value Leading to over $3.4 Billion in Successful Exits</p><p>White Bear Lake, Minnesota--(Newsfile Corp. - April 16, 2026) - <a href="https://api.newsfilecorp.com/redirect/ejKDBuMbrL">Envoy Medical&#174;, Inc.</a>&#160;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/COCH">COCH</a>) ("Envoy Medical"), a hearing health company pioneering fully implanted hearing solutions, today announced the appointment of Chas McKhann, a seasoned medical technology executive with documented success, to its Board of Directors.</p><p>Mr. McKhann is a well-known and respected med tech leader with extensive experience creating and executing commercialization plans that have scaled into high-growth companies creating significant shareholder value. Most recently, he served as Chief Executive Officer of Silk Road Medical, which sold to Boston Scientific for $1.16 Billion, and Apollo Endosurgery, which also sold to Boston Scientific for approximately $615 million. Prior to those roles, Mr. McKhann served as the Chief Commercial Officer of Torax Medical and Intersect ENT prior to their acquisitors by Johnson and Johnson and Medtronic, respectively. </p><p>"We are extremely excited to welcome Chas to our Board," said Brent Lucas, CEO of Envoy Medical. "Chas brings a proven track record of commercial success and delivering strong outcomes for investors. We look forward to benefitting from his deep industry knowledge and experience to advance our mission of bringing our first-of-its-kind fully implanted cochlear implant to the millions of patients who are not treating their hearing loss. Adding his experience and perspective will further strengthen our strategic positioning and visibility."</p><p>Mr. McKhann currently serves as Executive Chair of Distalmotion SA, an independent director at Exagen Inc., and is a Senior Advisor to McKinsey &#38; Company. Mr. McKhann holds an MBA from the Stanford University Graduate School of Business and a BA in Political Science from Stanford University.</p><p>"I am thrilled to be joining the Envoy Medical team," said Mr. McKhann.  "As a first-of-its-kind fully implanted Cochlear implant, I believe the Acclaim&#174; device has the ability to be a true game-changing advancement that has the potential to transform the lives of patients with hearing loss.  With the pivotal trial enrollment now complete, I am excited to work with Brent and his team to develop a commercialization strategy and launch plan that maximizes the patient impact of this amazing technology."</p><p>In addition to his role as an Independent Director, Mr. McKhann will also serve as a member of the Company's Compensation Committee. </p><p>The Acclaim&#174; cochlear implant received Breakthrough Device Designation from the FDA in 2019 and is currently under investigation as part of a U.S. based pivotal clinical trial. For more information on the trial, visit <a href="https://api.newsfilecorp.com/redirect/A8rDOfp0kw" target="_new">www.envoymedical.com/acclaim-pivotal</a>.</p><p>To be added to the Envoy Medical email distribution list, please email <a href="mailto:Envoy@kcsa.com">Envoy@kcsa.com</a> with COCH in the subject line.</p><p><b>About Envoy Medical, Inc.</b><br />Envoy Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/COCH">COCH</a>) is a hearing health company focused on providing innovative technologies across the hearing loss spectrum. Envoy Medical has pioneered one-of-a-kind, fully implanted devices for hearing loss, including its fully implanted Esteem&#174; active middle ear implant, commercially available in the U.S. since 2010, and the fully implanted Acclaim&#174; cochlear implant, an investigational device. Envoy Medical is dedicated to pushing hearing technology beyond the status quo to improve access, usability, compliance, and ultimately quality of life.</p><p><b>About the Fully Implanted Acclaim&#174; Cochlear Implant<br /></b>We believe the fully implanted Acclaim Cochlear Implant ("Acclaim CI") is a first-of-its-kind hearing device. Envoy Medical's fully implanted technology includes a sensor designed to leverage the natural anatomy of the ear instead of a microphone to capture sound.</p><p>The Acclaim CI is designed to address severe to profound sensorineural hearing loss that is not adequately addressed by hearing aids. The Acclaim CI is expected to be indicated for adults who have been deemed adequate candidates by a qualified physician.</p><p>The Acclaim Cochlear Implant received the Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) in 2019.</p><p><b>CAUTION The fully implanted Acclaim Cochlear Implant is an investigational device. Limited by Federal (or United States) law to investigational use.</b></p><p><b>About the Esteem&#174; Fully Implanted Active Middle Ear Implant (FI-AMEI)<br /></b>The Esteem fully implanted active middle ear implant (FI-AMEI) is the only FDA-approved, fully implanted&#x2A; hearing device for adults diagnosed with moderate to severe sensorineural hearing loss allowing for 24/7 hearing capability using the ear's natural anatomy. The Esteem FI-AMEI hearing implant is invisible and requires no externally worn components and nothing is placed in the ear canal for it to function. Unlike hearing aids, you never put it on or take it off. You can't lose it. You don't clean it. The Esteem FI-AMEI hearing implant offers true 24/7 hearing.</p><p>&#x2A;Once activated, the external Esteem FI-AMEI Personal Programmer is not required for daily use.</p><p>Important safety information for the Esteem FI-AMEI can be found at: <a href="https://api.newsfilecorp.com/redirect/87ZEJhOpVe">https://www.envoymedical.com/safety-information</a>. </p><p><b>Additional Information and Where to Find It<br /></b>Copies of the documents filed by Envoy Medical with the SEC may be obtained free of charge at the SEC's website at <a href="https://api.newsfilecorp.com/redirect/y4Z18SbmWo">www.sec.gov</a>.</p><p><b>Forward-Looking Statements<br /></b>This press release includes "forward-looking statements" within the meaning of the "safe harbor" provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-Looking statements may be identified by the use of words such as "estimate," "plan," "project," "forecast," "intend," "will," "expect," "anticipate," "believe," "seek," "target" or other similar expressions that predict or indicate future events or trends or that are not statements of historical matters, but the absence of these words does not mean that a statement is not forward-looking. Such statements may include, but are not limited to, statements regarding the expectations of Envoy Medical concerning the outlook for its business, productivity, plans and goals for future operations; the ability to obtain additional patents and develop future products or product improvements; the ability to maintain compliance with Nasdaq rules and requirements; the timing and future outcome of its FDA pivotal trial; the ability to raise capital and the amount of capital required to complete the FDA pivotal trial and early commercialization; the Acclaim CI being the first to market fully implanted cochlear implant; the timing and results of activations, enrollments, follow-up visits, data, and clinical trials of the Acclaim CI; and the participation or any changes or delays in participation of any subjects, institutions, or healthcare professionals in such trials; the safety, performance, and market acceptance of the Acclaim CI; the timing and results of the Acclaim CI's PMA submission to the FDA; the size of Envoy Medical's addressable market, operational performance, future market conditions or economic performance and developments in the capital and credit markets; and any information concerning possible or assumed future operations of Envoy Medical. The forward-looking statements contained in this press release reflect Envoy Medical's current views about future events and are subject to numerous known and unknown risks, uncertainties, assumptions and changes in circumstances that may cause its actual results to differ significantly from those expressed in any forward-looking statement. Envoy Medical does not guarantee that the events described will happen as described (or that they will happen at all). These forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to changes in the market price of shares of Envoy Medical's Class A Common Stock; changes in or removal of Envoy Medical's shares inclusion in any index; Envoy Medical's success in retaining or recruiting, or changes required in, its officers, key employees or directors; unpredictability in the medical device industry, the regulatory process to approve medical devices, and the clinical development process of Envoy Medical products; the ability to engage competition in the medical device industry, and the failure to introduce new products and services in a timely manner or at competitive prices to compete successfully against competitors; disruptions in relationships with Envoy Medical's suppliers, or disruptions in Envoy Medical's own production capabilities for some of the key components and materials of its products; changes in the need for capital and the availability of financing and capital to fund these needs; changes in interest rates or rates of inflation; legal, regulatory and other proceedings could be costly and time-consuming to defend; changes in applicable laws or regulations, or the application thereof on Envoy Medical; a loss of any of Envoy Medical's key intellectual property rights or failure to adequately protect intellectual property rights; the effects of catastrophic events, including war, terrorism and other international conflicts; and other risks and uncertainties set forth in the section entitled "Risk Factors" and "Cautionary Note Regarding Forward-Looking Statements" in the Annual Report on Form 10-K filed by Envoy Medical on March 23, 2026, and in other reports Envoy Medical files, with the SEC. If any of these risks materialize or Envoy Medical's assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. While forward-looking statements reflect Envoy Medical's good faith beliefs, they are not guarantees of future performance. Envoy Medical disclaims any obligation to publicly update or revise any forward-looking statement to reflect changes in underlying assumptions or factors, new information, data or methods, future events or other changes after the date of this press release, except as required by applicable law. You should not place undue reliance on any forward-looking statements, which are based only on information currently available to Envoy Medical.</p><div id="contactInfo"><p><b>Investor Contact<br /></b>Phil Carlson<br />KCSA Strategic Communications<br />O: 212.896.1233<br />E: <a href="mailto:Envoy@kcsa.com">Envoy@kcsa.com</a></p><p><b>Media Contact<br /></b>Anne Donohoe<br />KCSA Strategic Communications<br />O: 732-620-0033<br />E: <a href="mailto:Envoy@kcsa.com">Envoy@kcsa.com</a></p></div><p id="corporateNewsLogoContainer"><img src="https://images.newsfilecorp.com/files/9955/292772_a570098d74e18a38_logo.jpg" id="corporateNewsLogo" alt="Corporate Logo" /></p><p id="corporateLinkBack">To view the source version of this press release, please visit <a href="https://api.newsfilecorp.com/redirect/1KZMDsR7Jy">https://www.newsfilecorp.com/release/292772</a></p><p><img src="https://api.newsfilecorp.com/newsinfo/292772/197" alt="" /></p>

COCH

Envoy Medical Appoints Chas McKhann to Board of Directors

Envoy Medical Strengthens Board with Industry Leader Chas McKhann

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>Proven Med Tech Leader with an Established Track Record of Commercial Success and Optimizing Shareholder Value Leading to over $3.4 Billion in Successful ExitsWhite Bear Lake, Minnesota--(Newsfile Corp. - April 16, 2026)</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>Envoy Medical has appointed Chas McKhann to its Board, enhancing its advisory capabilities as it advances the commercialization of the Acclaim cochlear implant. Given McKhann&#039;s proven success in med tech, his involvement could significantly bolster Envoy&#039;s strategic positioning and shareholder value, particularly with the pivotal trial for Acclaim now complete.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>Envoy Medical appoints Chas McKhann to Board of Directors.</li><li>McKhann has a strong med tech background with multiple successful exits.</li><li>The pivotal trial for the Acclaim cochlear implant is complete.</li><li>Acclaim received FDA Breakthrough Device Designation in 2019.</li><li>Envoy aims to commercialize Acclaim, addressing severe hearing loss.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>Boston Scientific (BSX)</strong>: Acquisition of Silk Road Medical and Apollo Endosurgery reflects market confidence in medical devices.</li><li><strong>Johnson &amp; Johnson (JNJ)</strong>: Past acquisitions in med tech signal high value in innovative hearing solutions.</li><li><strong>Medtronic (MDT)</strong>: Acquisition history indicates a strong market for successful medical innovations.</li></ul>
  </section>

  <section data-block="category">
    <h3>Corporate Developments</h3>
    <p>This news falls under Corporate Developments as it involves key leadership changes and strategic positioning in the med tech industry. The appointment of McKhann enhances the company&#039;s credibility and might influence future innovations and market capture.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>Completion of pivotal trial could accelerate FDA approval process for Acclaim.</li><li>Appointment of McKhann may improve investor confidence and company strategy.</li><li>Potential commercialization of Acclaim could open up significant revenue streams.</li><li>Breakthrough Device Designation positions Acclaim favorably against competitors.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>Chas McKhann appointed to Envoy Medical Board on April 16, 2026.</li><li>Acclaim cochlear implant received FDA Breakthrough Device Designation in 2019.</li><li>Pivotal trial enrollment for Acclaim is now complete.</li><li>McKhann led companies generating over $3.4 billion in successful exits.</li><li>Envoy Medical focuses on fully implanted hearing solutions.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>COCH is a buy as clinical progress and leadership changes enhance growth prospects in the next 12 months.</p>
  </section>
</section>


<p>Proven Med Tech Leader with an Established Track Record of Commercial Success and Optimizing Shareholder Value Leading to over $3.4 Billion in Successful Exits</p><p>White Bear Lake, Minnesota--(Newsfile Corp. - April 16, 2026) - <a href="https://api.newsfilecorp.com/redirect/ejKDBuMbrL">Envoy Medical&#174;, Inc.</a>&#160;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/COCH">COCH</a>) ("Envoy Medical"), a hearing health company pioneering fully implanted hearing solutions, today announced the appointment of Chas McKhann, a seasoned medical technology executive with documented success, to its Board of Directors.</p><p>Mr. McKhann is a well-known and respected med tech leader with extensive experience creating and executing commercialization plans that have scaled into high-growth companies creating significant shareholder value. Most recently, he served as Chief Executive Officer of Silk Road Medical, which sold to Boston Scientific for $1.16 Billion, and Apollo Endosurgery, which also sold to Boston Scientific for approximately $615 million. Prior to those roles, Mr. McKhann served as the Chief Commercial Officer of Torax Medical and Intersect ENT prior to their acquisitors by Johnson and Johnson and Medtronic, respectively. </p><p>"We are extremely excited to welcome Chas to our Board," said Brent Lucas, CEO of Envoy Medical. "Chas brings a proven track record of commercial success and delivering strong outcomes for investors. We look forward to benefitting from his deep industry knowledge and experience to advance our mission of bringing our first-of-its-kind fully implanted cochlear implant to the millions of patients who are not treating their hearing loss. Adding his experience and perspective will further strengthen our strategic positioning and visibility."</p><p>Mr. McKhann currently serves as Executive Chair of Distalmotion SA, an independent director at Exagen Inc., and is a Senior Advisor to McKinsey &#38; Company. Mr. McKhann holds an MBA from the Stanford University Graduate School of Business and a BA in Political Science from Stanford University.</p><p>"I am thrilled to be joining the Envoy Medical team," said Mr. McKhann.  "As a first-of-its-kind fully implanted Cochlear implant, I believe the Acclaim&#174; device has the ability to be a true game-changing advancement that has the potential to transform the lives of patients with hearing loss.  With the pivotal trial enrollment now complete, I am excited to work with Brent and his team to develop a commercialization strategy and launch plan that maximizes the patient impact of this amazing technology."</p><p>In addition to his role as an Independent Director, Mr. McKhann will also serve as a member of the Company's Compensation Committee. </p><p>The Acclaim&#174; cochlear implant received Breakthrough Device Designation from the FDA in 2019 and is currently under investigation as part of a U.S. based pivotal clinical trial. For more information on the trial, visit <a href="https://api.newsfilecorp.com/redirect/A8rDOfp0kw" target="_new">www.envoymedical.com/acclaim-pivotal</a>.</p><p>To be added to the Envoy Medical email distribution list, please email <a href="mailto:Envoy@kcsa.com">Envoy@kcsa.com</a> with COCH in the subject line.</p><p><b>About Envoy Medical, Inc.</b><br />Envoy Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/COCH">COCH</a>) is a hearing health company focused on providing innovative technologies across the hearing loss spectrum. Envoy Medical has pioneered one-of-a-kind, fully implanted devices for hearing loss, including its fully implanted Esteem&#174; active middle ear implant, commercially available in the U.S. since 2010, and the fully implanted Acclaim&#174; cochlear implant, an investigational device. Envoy Medical is dedicated to pushing hearing technology beyond the status quo to improve access, usability, compliance, and ultimately quality of life.</p><p><b>About the Fully Implanted Acclaim&#174; Cochlear Implant<br /></b>We believe the fully implanted Acclaim Cochlear Implant ("Acclaim CI") is a first-of-its-kind hearing device. Envoy Medical's fully implanted technology includes a sensor designed to leverage the natural anatomy of the ear instead of a microphone to capture sound.</p><p>The Acclaim CI is designed to address severe to profound sensorineural hearing loss that is not adequately addressed by hearing aids. The Acclaim CI is expected to be indicated for adults who have been deemed adequate candidates by a qualified physician.</p><p>The Acclaim Cochlear Implant received the Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) in 2019.</p><p><b>CAUTION The fully implanted Acclaim Cochlear Implant is an investigational device. Limited by Federal (or United States) law to investigational use.</b></p><p><b>About the Esteem&#174; Fully Implanted Active Middle Ear Implant (FI-AMEI)<br /></b>The Esteem fully implanted active middle ear implant (FI-AMEI) is the only FDA-approved, fully implanted&#x2A; hearing device for adults diagnosed with moderate to severe sensorineural hearing loss allowing for 24/7 hearing capability using the ear's natural anatomy. The Esteem FI-AMEI hearing implant is invisible and requires no externally worn components and nothing is placed in the ear canal for it to function. Unlike hearing aids, you never put it on or take it off. You can't lose it. You don't clean it. The Esteem FI-AMEI hearing implant offers true 24/7 hearing.</p><p>&#x2A;Once activated, the external Esteem FI-AMEI Personal Programmer is not required for daily use.</p><p>Important safety information for the Esteem FI-AMEI can be found at: <a href="https://api.newsfilecorp.com/redirect/87ZEJhOpVe">https://www.envoymedical.com/safety-information</a>. </p><p><b>Additional Information and Where to Find It<br /></b>Copies of the documents filed by Envoy Medical with the SEC may be obtained free of charge at the SEC's website at <a href="https://api.newsfilecorp.com/redirect/y4Z18SbmWo">www.sec.gov</a>.</p><p><b>Forward-Looking Statements<br /></b>This press release includes "forward-looking statements" within the meaning of the "safe harbor" provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-Looking statements may be identified by the use of words such as "estimate," "plan," "project," "forecast," "intend," "will," "expect," "anticipate," "believe," "seek," "target" or other similar expressions that predict or indicate future events or trends or that are not statements of historical matters, but the absence of these words does not mean that a statement is not forward-looking. Such statements may include, but are not limited to, statements regarding the expectations of Envoy Medical concerning the outlook for its business, productivity, plans and goals for future operations; the ability to obtain additional patents and develop future products or product improvements; the ability to maintain compliance with Nasdaq rules and requirements; the timing and future outcome of its FDA pivotal trial; the ability to raise capital and the amount of capital required to complete the FDA pivotal trial and early commercialization; the Acclaim CI being the first to market fully implanted cochlear implant; the timing and results of activations, enrollments, follow-up visits, data, and clinical trials of the Acclaim CI; and the participation or any changes or delays in participation of any subjects, institutions, or healthcare professionals in such trials; the safety, performance, and market acceptance of the Acclaim CI; the timing and results of the Acclaim CI's PMA submission to the FDA; the size of Envoy Medical's addressable market, operational performance, future market conditions or economic performance and developments in the capital and credit markets; and any information concerning possible or assumed future operations of Envoy Medical. The forward-looking statements contained in this press release reflect Envoy Medical's current views about future events and are subject to numerous known and unknown risks, uncertainties, assumptions and changes in circumstances that may cause its actual results to differ significantly from those expressed in any forward-looking statement. Envoy Medical does not guarantee that the events described will happen as described (or that they will happen at all). These forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to changes in the market price of shares of Envoy Medical's Class A Common Stock; changes in or removal of Envoy Medical's shares inclusion in any index; Envoy Medical's success in retaining or recruiting, or changes required in, its officers, key employees or directors; unpredictability in the medical device industry, the regulatory process to approve medical devices, and the clinical development process of Envoy Medical products; the ability to engage competition in the medical device industry, and the failure to introduce new products and services in a timely manner or at competitive prices to compete successfully against competitors; disruptions in relationships with Envoy Medical's suppliers, or disruptions in Envoy Medical's own production capabilities for some of the key components and materials of its products; changes in the need for capital and the availability of financing and capital to fund these needs; changes in interest rates or rates of inflation; legal, regulatory and other proceedings could be costly and time-consuming to defend; changes in applicable laws or regulations, or the application thereof on Envoy Medical; a loss of any of Envoy Medical's key intellectual property rights or failure to adequately protect intellectual property rights; the effects of catastrophic events, including war, terrorism and other international conflicts; and other risks and uncertainties set forth in the section entitled "Risk Factors" and "Cautionary Note Regarding Forward-Looking Statements" in the Annual Report on Form 10-K filed by Envoy Medical on March 23, 2026, and in other reports Envoy Medical files, with the SEC. If any of these risks materialize or Envoy Medical's assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. While forward-looking statements reflect Envoy Medical's good faith beliefs, they are not guarantees of future performance. Envoy Medical disclaims any obligation to publicly update or revise any forward-looking statement to reflect changes in underlying assumptions or factors, new information, data or methods, future events or other changes after the date of this press release, except as required by applicable law. You should not place undue reliance on any forward-looking statements, which are based only on information currently available to Envoy Medical.</p><div id="contactInfo"><p><b>Investor Contact<br /></b>Phil Carlson<br />KCSA Strategic Communications<br />O: 212.896.1233<br />E: <a href="mailto:Envoy@kcsa.com">Envoy@kcsa.com</a></p><p><b>Media Contact<br /></b>Anne Donohoe<br />KCSA Strategic Communications<br />O: 732-620-0033<br />E: <a href="mailto:Envoy@kcsa.com">Envoy@kcsa.com</a></p></div><p id="corporateNewsLogoContainer"><img src="https://images.newsfilecorp.com/files/9955/292772_a570098d74e18a38_logo.jpg" id="corporateNewsLogo" alt="Corporate Logo" /></p><p id="corporateLinkBack">To view the source version of this press release, please visit <a href="https://api.newsfilecorp.com/redirect/1KZMDsR7Jy">https://www.newsfilecorp.com/release/292772</a></p><p><img src="https://api.newsfilecorp.com/newsinfo/292772/197" alt="" /></p>

Envoy Medical has appointed Chas McKhann to its Board, enhancing its advisory capabilities as it advances the commercialization of the Acclaim cochlear implant. Given McKhann's proven success in med tech, his involvement could significantly bolster Envoy's strategic positioning and shareholder value, particularly with the pivotal trial for Acclaim now complete.

Envoy Medical Appoints Chas McKhann to Board of Directors

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Corporate Developments

Related News